News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ReGen Biologics, Inc. (RGBI) Reports Successful Q1 Training Results



4/9/2009 9:43:32 AM

HACKENSACK, N.J.--(BUSINESS WIRE)--ReGen Biologics (OTC: RGBO) (“ReGen” or “the Company”) announced today that it has trained 45 sports medicine surgeons in the use of its Menaflex™ collagen meniscus implant and over 30 sales representatives during the first three months of 2009. ReGen initiated U.S. training efforts in January 2009 after receiving FDA clearance of the Menaflex for the medial meniscus on December 18, 2008.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES